4//SEC Filing
Bellinger Andrew 4
Accession 0001209191-23-010127
CIK 0001840574other
Filed
Feb 15, 7:00 PM ET
Accepted
Feb 16, 5:00 PM ET
Size
5.4 KB
Accession
0001209191-23-010127
Insider Transaction Report
Form 4
Bellinger Andrew
Chief Scientific Officer
Transactions
- Award
Stock Option (right to buy)
2023-02-14+182,800→ 182,800 totalExercise: $21.76Exp: 2033-02-13→ Common Stock (182,800 underlying)
Footnotes (1)
- [F1]The option was granted on February 14, 2023. 25% of the shares underlying the option will vest on February 14, 2024, and the remainder are scheduled to vest in equal monthly installments thereafter until February 14, 2027.
Documents
Issuer
Verve Therapeutics, Inc.
CIK 0001840574
Entity typeother
Related Parties
1- filerCIK 0001864116
Filing Metadata
- Form type
- 4
- Filed
- Feb 15, 7:00 PM ET
- Accepted
- Feb 16, 5:00 PM ET
- Size
- 5.4 KB